Vedana Therapeutics raises $46 million in Series A funding led by Westlake BioPartners and Canaan Partners to develop innovative migraine therapies.
Amount Raised
$46 Million
Round Type
Series A
SeattleBiotechnologyHealth CareTherapeuticsInvestors
Description
Vedana Therapeutics has secured $46 million in Series A financing to advance its next-generation therapies for migraine prevention. The financing was co-led by Westlake BioPartners and Canaan Partners, with support from Dawn Biopharma and Alexandria Venture Investments. The funds will help Vedana develop potentially best-in-class antibodies targeting clinically validated pathways for migraine control. The company's leadership includes experts who have significantly contributed to migraine therapy advancements.
Quick answer
Vedana Therapeutics raised $46 Million in a Series A round, dated June 17, 2026. Investors: Alexandria Venture Investments, Dawn Biopharma, Canaan Partners and Westlake BioPartners. Vedana Therapeutics is based in Seattle, Washington, United States.
- How much did Vedana Therapeutics raise?
- Vedana Therapeutics raised $46 Million in a Series A round on June 17, 2026.
- Who invested in Vedana Therapeutics?
- Alexandria Venture Investments, Dawn Biopharma, Canaan Partners and Westlake BioPartners are named as investors in this round.
- What does Vedana Therapeutics do?
- Vedana Therapeutics is a biotechnology company focused on developing next-generation therapies for migraine prevention.
- Where is Vedana Therapeutics based and how big is it?
- Vedana Therapeutics is based in Seattle, Washington, United States.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Vedana Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Ratio Therapeutics raised $70M (Series C) on July 31, 2026.
- Hyku Biosciences raised $8.6M on July 30, 2026.
- HCW Biologics raised $1.5M (Post-IPO Equity) on July 29, 2026.
- Adjuvia Therapeutics raised $8M (Seed) on July 29, 2026.
- CORE Biomedicine raised $21M (Series A) on July 28, 2026.
- Torrey Pines Medicine raised an undisclosed amount (Angel) on July 28, 2026.
Who to call at Vedana Therapeutics, and when
A new round usually means Vedana Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Vedana Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Vedana Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Vedana Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Vedana Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansVedana Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.